Effect of the Transcranial Direct Current Stimulation (tDCS) on Dependent Smoking People

Evaluation de l'Effet de la Stimulation Transcranienne en Courant Continu Chez Les Personnes Tabagiques dépendantes

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02867514

Acronym

TabaSCo

Enrollment

100

Registered

2016-08-16

Start date

2014-03-31

Completion date

2017-07-31

Last updated

2016-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tobacco Abuse Smoke

Keywords

tobacco, craving, tDCS, attentional tasks

Brief summary

The purpose of this study is to evaluate the effect of 10 sessions of anodal transcranial Direct Current Stimulation (tDCS - 1 mA) applied to left vs right CDLPF of tobacco-dependent subjects compared to the application of a placebo tDCS (sham procedure) on the craving, which is evaluated by the item 1 of Fagerström test between day 1 and day 10. Craving is also evaluated 1 month post-treatment.

Detailed description

Tobacco is the second leading cause of death worldwide. It is currently responsible for the death of one in 10 adults (about 5 million deaths per year) and it is the fourth disease risk factor in the world. Many methods to quit smoking are available but in all cases, relapse is a common phenomena. The main risk factor for relapse is craving. So, acting on the craving seems essential to modulate tobacco consumption. Many functional neuroimaging studies have established a neuroanatomical substrate for craving process, in particularly dorsolateral prefrontal cortex (DLPFC), accessible par neuromodulation.

Interventions

DEVICEtranscranial Direct Current Stimulation (tDCS)

After locating the stimulation areas, treatment will be delivered during 30-minute session. Treatment will be occur 1 session per day during 10 days (5 days per week during 2 successive weeks). Subjects will be monitored during tDCS for any side effects or adverse events.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

20 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Fagerström score ≥ 5 * Q-MAT score ≥ 6 * smoking subjects from 10 to 30 cigarettes a day * right-handed subjects * w/o severe progressive somatic pathology (especially tumor diseases, degenerative diseases) * Hamilton Depression Rating Scale-17 score \<18

Exclusion criteria

* pregnancy and/or lactation * presence of a specific contraindication for tDCS (e.g. personal history of epilepsy, metallic head implant, cardiac pacemaker...)

Design outcomes

Primary

Measure	Time frame	Description
change from baseline in craving evaluated by item 1 of Fagerström test	baseline, day 10 and 1 month post-ttt	before and after the 10 sessions

Countries

France

Contacts

Primary ContactEmmanuel Haffen, Prof

emmanuel.haffen@univ-fcomte.fr+33381219007

Backup ContactMagali Nicolier, PhD

mnicolier@chu-besancon.fr+33381219007

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026